Loading stock…

Recursion Pharmaceuticals, Inc. (RXRX) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Recursion Pharmaceuticals, Inc.

RXRXMarket cap $2.29BPrice $4.3

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Recursion Pharmaceuticals uses AI and robotics to screen millions of drug combinations, turning biology into massive datasets. It's essentially trying to make drug discovery an industrial, automated process instead of a slow, manual guessing game scientists have relied on for decades.

In Bastion Portfolios?

52W Return-27%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+23%9

Revenue Forecast

Rev CAGR (1y)-56%1

Rev CAGR (3y)-15%1

Rev CAGR (5y)+37%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-1003%1

Net Income Margin-946%1

Free Cash Flow Margin-642%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-57%1

ROA-41%1

Earnings Stabilityna–

GEAR+VERY WEAK2

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV2.56

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-15.4%1

Dividend Yieldna–

Momentum

Short term

1 month return+24%10

3 month return+15%9

YTD return+4%6

Mid term

Price vs 52wHigh59%2

1 year return-30%2

Long term

3 year return-39%1

5 year return-77%1

Risk Shield

Price Risk

Beta3.11

Volatility75%1

Free Cash Flow

Free Cash Flow Margin-642%1

Free Cash Flow Yield-15.4%1

Quality

ROCE-49%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

RXRXRecursion Pharmaceuticals

Revenue FY25$75M

GROWTH RATING↗

WEAK31 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+23%9

Revenue, next 1Y-56%1

Revenue, next 3Y, CAGR-15%1

Revenue, next 5Y, CAGR+37%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 23%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

The runway holds up: revenue is set to grow 37%/yr over five years.10/10

WATCH

Revenue is set to shrink 15%/yr over the next 3 years, a little behind the market.4/10

WEAKNESSES

Growth is the weak spot here, trailing 69% of companies worldwide.

Revenue grew 23%/yr over the last 3 years, but it is set to shrink 15%/yr from here.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Maturing Grower

Growth is a weak point here: a business heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK28 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+24%10

3-month return+15%9

YTD return+4%6

MID & LONG-TERM▾SCORE

% of 52-week high59%2

1-year return-30%2

3-year return-39%1

5-year return-77%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+24%) and over three months (+15%).

WATCH

Returns sit at the market level so far this year (+4%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-39% over three years and -77% over five), behind 90% of the market.

It's down 30% over the past year, now 41% below its 52-week high. That is lagging the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Recursion Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

RXRXRecursion Pharmaceuticals

Revenue FY25$75M

GROWTH RATING↗

WEAK31 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+23%9

Revenue, next 1Y-56%1

Revenue, next 3Y, CAGR-15%1

Revenue, next 5Y, CAGR+37%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 23%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

The runway holds up: revenue is set to grow 37%/yr over five years.10/10

WATCH

Revenue is set to shrink 15%/yr over the next 3 years, a little behind the market.4/10

WEAKNESSES

Growth is the weak spot here, trailing 69% of companies worldwide.

Revenue grew 23%/yr over the last 3 years, but it is set to shrink 15%/yr from here.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Maturing Grower

Growth is a weak point here: a business heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK28 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+24%10

3-month return+15%9

YTD return+4%6

MID & LONG-TERM▾SCORE

% of 52-week high59%2

1-year return-30%2

3-year return-39%1

5-year return-77%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+24%) and over three months (+15%).

WATCH

Returns sit at the market level so far this year (+4%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-39% over three years and -77% over five), behind 90% of the market.

It's down 30% over the past year, now 41% below its 52-week high. That is lagging the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Recursion Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community